Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 6/2006

01.06.2006 | Review Article

Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis

verfasst von: Andrei Barasch, Sharon Elad, Arnold Altman, Kathryn Damato, Joel Epstein

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2006

Einloggen, um Zugang zu erhalten

Abstract

This review focuses on the value of several groups of agents for the prevention and treatment of mucositis. The review refers to alimentary mucositis as a generalized term that includes oral mucositis and gastrointestinal mucositis. This paper is part of the systematic review made by the mucositis study group which operates in the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). Several new guidelines are suggested in this review as an update to the primary systematic review that was published by the same group in 2004.
Literatur
1.
Rubenstein EB, Peterson DE, Schubert MM, Keefe D, McGuire D, Epstein JB et al (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100(Suppl 9):2026–2046PubMedCrossRef
2.
Barasch A, Peterson DE (2003) Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol 39:91–100PubMedCrossRef
3.
Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert MM, Hauer-Jensen M et al (2004) Perspectives on cancer therapy-induced mucosal injury. Cancer 100(Suppl 9):1995–2025PubMedCrossRef
4.
Logan R (2002) Oral mucositis-current concepts and management. Roy Aust Coll Dent Surg 16:54–57
5.
6.
Luglie PF (2002) Prevention of periodontopathy and oral mucositis during antineoplastic chemotherapy. Minerva Stomatol 51:231–239PubMed
7.
Vokurka S, Bystricka E, Koza V, Scudlova J, Pavlicova V, Valentova D et al (2005) The comparative effects of povidone-iodine and normal saline mouthwashes on oral mucositis in patients after high-dose chemotherapy and APBSCT-results of a randomized multicentre study. Support Care Cancer 13:554–558PubMedCrossRef
8.
Adamietz IA, Rahn R, Bottcher HD et al (1998) Prophylaxis with povidone-iodine against induction of oral mucositis by radiochemistry. Support Care Cancer 6:373–377PubMedCrossRef
9.
Stockman MA (2003) Oral mucositis and selective elimination of oral flora in head and neck cancer patients receiving radiotherapy: a double-blind randomized clinical trial. Br J Cancer 88:1012–1016CrossRef
10.
El-Sayed S (2002) Prophylaxis of radiation-associated mucositis in conventionally treated patients with head and neck cancer: a double-blind, phase III randomized controlled trial evaluating the clinical efficacy of an antimicrobial lozenge using a validated mucositis scoring system. J Clin Oncol 20:3956–3963PubMedCrossRef
11.
Cheng KKF (2004) Prevention of oral mucositis in pediatric patients treated with chemotherapy: a randomized, cross-over trial comparing two protocols of oral care. Eur J Cancer 40:1208–1216PubMedCrossRef
12.
Melo de Brito Costa E (2003) Evaluation of an oral preventive protocol in children with acute lymphoblastic leukemia. Pesqui Odontol Bras 17:147–150CrossRef
13.
Dodd MJ (2003) Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate vs. salt and soda mouthwashes. Cancer Investig 21:21–33CrossRef
14.
Nottage M (2003) Sucralfate mouthwash for prevention and treatment of 5-florouracil-induced mucositis: a randomized placebo-controlled study. Support Care Cancer 11:41–47PubMed
15.
Demarosi F (2004) Transdermal fentanyl in hematopoietic stem cell transplant patients: an open trial using transdermal fentanyl for the treatment of oral mucositis pain. Bone Marrow Transplant 33:1247–1251PubMedCrossRef
16.
17.
Cerchietti LCA (2002) Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer 95:2230–2236PubMedCrossRef
18.
Shaiova I (2004) Tolerability and effects of two formulations of oral transmucosal fentanyl citrate in patients with radiation-induced oral mucositis. Support Care Cancer 12:268–273PubMedCrossRef
19.
Peterson DE, Petit R (2003) Phase III study: AES-14 in chemotherapy patients at risk for mucositis (abstract 2917). Prog Proc Am Soc Clin Oncol 22:725
20.
Pytlik R (2002) Standardized parenteral alanyl-glutamine dipeptide supplementation is not beneficial in autologous transplant patients: a randomized, double-blind placebo-controlled study. Bone Marrow Transplant 20:953–961CrossRef
21.
Thornley I (2004) A multiagent strategy to decrease regimen-related toxicity in children undergoing allogenic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 10:635–644PubMedCrossRef
22.
Bolwell B (2004) A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate moeftil for GVHD prophylaxis in myeloablative allogenic bone marrow transplantation. Bone Marrow Transplant 34:621–625PubMedCrossRef
23.
Cutler C (2004) Sirolimus and tacrolimus without methotrexate as GVHD prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10:328–336PubMedCrossRef
24.
van’t Land B (2004) Role of curcumin and the inhibition of NF-kB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia 18:276–284CrossRef
25.
Rezvani M (2004) Modification of radiation-induced acute oral mucositis in the rat. Int J Radiat Biol 80:177–182PubMedCrossRef
Metadaten
Titel
Antimicrobials, mucosal coating agents, anesthetics, analgesics, and nutritional supplements for alimentary tract mucositis
verfasst von
Andrei Barasch
Sharon Elad
Arnold Altman
Kathryn Damato
Joel Epstein
Publikationsdatum
01.06.2006
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2006
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0066-1

Weitere Artikel der Ausgabe 6/2006

Supportive Care in Cancer 6/2006 Zur Ausgabe

Review Article

Developing evidence-based guidelines for management of alimentary mucositis: process and pitfalls

Review Article

Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer

Review Article

Amifostine in the management of radiation-induced and chemo-induced mucositis

Editorial

Mucositis guidelines: what have they achieved, and where to from here?

Forthcoming Meetings

Forthcoming Meetings

Short Communication

Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise